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Genome-scale metabolic models (GEMs) are used extensively for
analysis of mechanisms underlying human diseases and metabolic
malfunctions. However, the lack of comprehensive and high-quality
GEMs for model organisms restricts translational utilization of omics
data accumulating from the use of various disease models. Here we
present a unified platform of GEMs that covers five major model
animals, including Mouse1 (Mus musculus), Rat1 (Rattus norvegi-
cus), Zebrafish1 (Danio rerio), Fruitfly1 (Drosophila melanogaster),
and Worm1 (Caenorhabditis elegans). These GEMs represent the
most comprehensive coverage of the metabolic network by consid-
ering both orthology-based pathways and species-specific reactions.
All GEMs can be interactively queried via the accompanying web
portal Metabolic Atlas. Specifically, through integrative analysis of
Mouse1 with RNA-sequencing data from brain tissues of transgenic
mice we identified a coordinated up-regulation of lysosomal GM2
ganglioside and peptide degradation pathways which appears to be
a signature metabolic alteration in Alzheimer’s disease (AD) mouse
models with a phenotype of amyloid precursor protein overexpres-
sion. This metabolic shift was further validated with proteomics
data from transgenic mice and cerebrospinal fluid samples from hu-
man patients. The elevated lysosomal enzymes thus hold potential
to be used as a biomarker for early diagnosis of AD. Taken together,
we foresee that this evolving open-source platform will serve as an
important resource to facilitate the development of systems medi-
cines and translational biomedical applications.
genome-scale model | animal model | Alzheimer’s disease | Aβ deposition |
translational medicine
Animal models have long been utilized as a fundamental toolfor translational research in recapitulating phenotypic syn-
dromes, clarifying underlying mechanisms, and translating bio-
medical discoveries into effective clinical treatments for human
disease (1). Small rodents, including mouse (Mus musculus) and
rat (Rattus norvegicus), account for 90% of the tens of millions of
animals used annually in medical research (2, 3), and transgenic
mice in particular are the most commonly used models for a
plethora of human diseases including cancers, neurodegenerative
dementia, diabetes, and many other metabolic disorders (4). In
addition, with their unique anatomical and physiological features
transgenic zebrafish (Danio rerio) and invertebrate models, such as
the fruit fly (Drosophila melanogaster) and Nematoda worm
(Caenorhabditis elegans), have been used for many years as inex-
pensive alternatives for studying human diseases through genetic
manipulation of ortholog genes (5, 6). It is also important to note
that nearly all the fundamental aspects of biology have been de-
rived from the study of model organisms (7).
A genome-scale metabolic model (GEM) is a mathematical
representation of the metabolism for an organism and it provides
extensive gene–reaction–metabolite connectivity via two matri-
ces: the S matrix for associating metabolites to reactions and the
rxnGeneMat matrix associating reactions to corresponding en-
zymes and genes (8). Given that many human diseases, including
cancer, type II diabetes, and many liver- and pancreas-related
diseases can be attributed to metabolic disorders (9), human
GEMs have been used to describe the metabolic conditions of
specific tissues and cell types at the systems level with the inte-
gration of omics data (10–13). For the purpose of clarity, hence-
forth “GEM” is used here to refer to a computational metabolic
model, and “model” refers to a transgenic animal developed for
studying human disease.
The use of animal models together with GEMs poses an at-
tractive approach to studying human disease. For example, mouse
GEMs have previously been applied to investigate the influences
of gut microbiota on host metabolism (14). To date, there have
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been a few existing GEMs for model animals, including MMR
(14) and iMM1865 (15) for mouse, iRno (16) for rat, ZebraGEM
(17, 18) for zebrafish, and iCEL1273 and iCEL1314 for worm (19,
20). However, these GEMs have not been developed and publicly
curated to the same extent as that of yeast (21) and human (11).
Their limited coverage in metabolic pathways and incompatible
nomenclatures impede cross-species validation of biological dis-
coveries and translational applications from animal models to
human patients.
Recently, an open and version-controlled workflow has been in-
troduced during the development of the most comprehensive yeast
and human GEM, Yeast8 (21) and Human1 (11), respectively,
which present high-quality templates to develop new GEMs in a
systematic and reproducible manner. Databases such as MGD (22),
FlyBase (23), ZFIN (24), and WormBase (25) that provide
organism-specific annotation and human orthologs have been re-
cently integrated into a centralized portal, the Alliance of Genome
Resources (26), for consistent annotation and curation of gene on-
tology in relation to the human counterparts. Through channeling
these reliable data sources we here present a unified GEM platform
for mouse, rat, zebrafish, fruit fly, and worm. The derived GEMs
(Mouse1, Rat1, Zebrafish1, Fruitfly1, and Worm1, respectively)
were reconstructed from a robust modeling pipeline that combines
both the orthology-based metabolic network and species-specific
pathways. To validate this approach, we conducted an extensive
GEM comparison and gene essentiality analysis using available ex-
perimental data and demonstrated that our GEMs generally out-
perform the previous ones. We also showcased the usefulness of
Mouse1 in systems medicine discovery by performing integrative
analysis of omics data from mouse models of Alzheimer’s disease
(AD). We are confident that this versatile GEM platform covering
all major model animals will greatly enhance the utilization of omics
data from disease models in facilitating translational studies.
Results
GEM Reconstruction, Exploration, and Curation for Model Animals.
We developed a pipeline that combines various reliable data
sources and generates a coherent collection of GEMs for major
model animals, including mouse (M. musculus), rat (R. norvegicus),
zebrafish (D. rerio), fruit fly (D. melanogaster), and Nematoda
worm (C. elegans) (Fig. 1 and SI Appendix, Fig. S1). In this pipeline,
the open-curated generic human GEM, Human1 (11), was used as
a template. The well-annotated orthologs and paralogs associated
from human to the five model organisms, as well as evaluating
features bestForward, bestReverse, andmethodCount (the number of
different methods used in determining the orthologs), were re-
trieved from the Alliance Genomes databases using the stringent
criteria provided (26). All one-to-one pairs were kept, while the
one-to-multiple pairs were filtered with the following criteria: 1)
exclude the pairs that are neither bestforward nor bestReverse and
2) only keep the pairs that are both the best froward and reverse
hits. If steps 1 and 2 exclude all hits for a query gene, then we
retrieved and kept the ortholog pair(s) with the highest method-
Count. Using the RAVEN toolbox (27), the species-specific re-
actions and metabolites for each animal were extracted from the
KEGG (Kyoto Encyclopedia of Genes and Genomes) database
and manually inspected for integration (SI Appendix). Here, we
report the first releases of these simulation-ready animal GEMs as
Mouse1, Rat1, Zebrafish1, Fruitfly1 and Worm1, respectively
(Fig. 1 and Dataset S1).
These new GEMs were integrated into the accompanying web
portal Metabolic Atlas (https://metabolicatlas.org/), which allows
for interactive exploration and cross-species comparison of the
GEMs through the GEM Browser, a tabular interface; the Map
Viewer, a collection of manually curated two-dimensional maps
and automated three-dimensional maps; and the Interaction
Partners tool, a network view of gene-metabolite associations.
Furthermore, the relational database (PostgreSQL) powering the
Metabolic Atlas portal was replaced by a graph implementation
(Neo4j), enabling new features such as GEM comparison via ex-
ternal identifiers. These improvements are released as Metabolic
Atlas 2.0, which is open-source with the running website, graph
database integration, upgraded three-dimensional viewer, and all
data files publicly available (SI Appendix).
To facilitate open curation and continuous integration of bio-
chemical knowledge from the research community, these GEMs
are tightly integrated with GitHub (see Data Availability) in com-
plying with the “standard-GEM” specifications (28), which defines
a set of requirements and recommendations for versioning GEMs




Fig. 1. Genome-scale metabolic modeling for model animals. A reconstruction approach of combining (A) ortholog-GEMs derived from the Human1
template and (B) species-specific metabolic networks extracted from the KEGG database by the RAVEN package was used to obtain (C) the model animal
GEMs that were deposited on GitHub according to the standard-GEM scheme (28).
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GEM Comparison, Evaluation, and Validation. As generated by a
coherent pipeline in which all primary identifiers belong to the
same namespace, the new generic GEMs can be compared under a
consistent scheme of subsystems (Fig. 2A). Despite the reduction in
the total number of reactions, Worm1 contained new phenyl-
propanoid biosynthesis pathway reactions, and the hormone bio-
synthesis pathway in Fruitfly1 was augmented, after the integration
of a species-specific metabolic network. Likewise, Mouse1 and
Rat1 are capable of de novo synthesis of vitamin C (ascorbate), a
metabolic feature retained in most rodent species but lost in hu-
mans (29). In addition, the primary identifiers of metabolites and
reactions from the new GEMs were all provided with the Meta-
NetX identifiers (30) for convenient comparison and expansion.
To validate these newly developed GEMs, we conducted a
systematic comparison with existing GEMs of the same species
(Fig. 2 and Dataset S1). For each species, the newly generated
GEMs obtained substantially expanded coverage in metabolic
components of genes, reactions, and metabolites, as well as ex-
tended complex-subunit information (Fig. 2 B–F). An exception
was the GEM BMID000000141998, which was produced from a
fully automatic pipeline and included more genes and metabo-
lites, but the quality of automatically generated GEMs is gen-
erally low due to lack of curation (31).
The quality of a GEM is often evaluated by predicting genes
that are essential to the viability of the organism and comparing
the predictions with experimental data. To validate our animal
GEM reconstruction pipeline, a gene essentiality analysis was
conducted for each species by comparing the predictive perfor-
mance of new and previous GEMs (Fig. 2G and Dataset S2). In
this analysis, the genes for a given GEM were individually
knocked out in silico to identify those that are essential for
biomass formation (cell viability). The prediction results were
then compared with gene essentiality data retrieved from the
Online Gene Essentiality (OGEE) database (32) to quantify the
number of true and false positives and negatives. The Matthews
correlation coefficient (MCC), a balanced metric of classification
performance (33), was calculated for the GEMs of mouse, fruit fly,
and worm, for which genome-scale experimental gene essentiality
data were available (Dataset S2). Mouse1 demonstrated a sub-
stantial improvement in essentiality predictions (MCC = 0.158)
compared to 0.09 and 0.03 for iMM1865 and MMR, respectively.
Fruitfly1 also showed a better predictive capacity than FlySilico, a
simple GEM covering only central carbon, amino acid, lipid, and
carbohydrate metabolism (31). The automatically generated GEM
BMID000000141998 predicted all genes as nonessential and
therefore had an undefined MCC value (Fig. 2G). For the worm
GEMs, Worm1 displayed improved prediction performance com-
pared to iCEL1273 (19) and equivalent to the very recent
iCEL1314, from which by incorporating the pathway for Ascaroside
biosynthesis and transportation (20). This further highlights the
importance of curation and more complete coverage of metabolism
in obtaining systems-level insights.
The MEMOTE scores (34), which were estimated from a se-
ries of tests on stoichiometric consistency, mass-balanced and
blocked reactions, associated annotations, and so on, were used
for benchmarking. The new GEMs outperformed the existing
GEMs for each species with regard to MEMOTE scores
(Fig. 2 B–F).
Integrative Metabolic Analysis of AD Models Using Mouse1. Due to
many attractive features (small and easy to handle, prolific breeder,
and amenable to genetic manipulation) of mice and high genomic
similarity to human, mouse models exist for a substantial number of
diseases (4). They are extremely useful in studying the conditions
for which patient samples and experiments are unfeasible or un-
ethical to obtain (e.g., neurodegenerative diseases). To date, there
are ∼200 different mouse models that have been developed for
understanding the mechanism of AD (35), which is the most
prevalent dementia affecting millions of people worldwide (36).
To demonstrate the utility of the GEMs developed using our
framework, Mouse1 was used to investigate different AD models
through omics data integration and gene set analysis (Fig. 3 and SI
Appendix, Figs. S2–S6). Using a detailed search of the GEO data-
base (SI Appendix), a total of 11 high-quality RNA-sequencing
(RNA-seq) datasets including both transgenic mice and wild-type
controls with paired time points were selected from six represen-
tative ADmodels (Fig. 3 A and B and Dataset S3). There were four
amyloid precursor protein (APP) overexpression models that re-
capitulate the major AD pathology (i.e., the formation of intracel-
lular plaques and tangles containing aggregated amyloid β (Aβ)
peptide and hyperphosphorylated tau protein), as well as two
Trem2KO models with a deleted Trem2 gene that had complete or
partial absence of the Aβ deposition phenotype. To make the fig-
ures simple and easy to understand, the models APPswe/
PSEN1dE9 (line 85) and APPswe/PSEN1dE9 (C57BL6) that have
identical genotype but use different mouse strains were merged and
the sample GEO IDs were consistently provided for clarification.
Next, we applied the task-driven integrative network inference al-
gorithm (tINIT) (37) to generate tissue- and cell-type-specific
GEMs, which combine the metabolic network determined by the
RNA-seq data of metabolic genes and the essential reactions re-
quired for all cell types (SI Appendix). A structural comparison
showed that the GEMs from APP overexpression models are
more homogeneous than those from Trem2KOmodels, regardless
of tissue source, gender, and age (Fig. 3C and SI Appendix, Fig.
S2). In contrast, the GEMs from Trem2KO model separated ex-
plicitly by cell types. GEMs from APP overexpression models were
characterized by an enhanced coverage of pathways including
cholesterol biosynthesis, beta oxidation of fatty acids, and amino
acid metabolism but reduced coverage of biopterin metabolism
(SI Appendix, Fig. S3). In addition, de novo synthesis of aspara-
gine, cystine, and cysteine and energy-associated functions were
reduced in Trem2KO model GEMs (SI Appendix, Fig. S4). In-
terestingly, the GEMs of the hybrid model that was developed by
crossing the Trem2KO and APPPS1 transgenic mice presented
different metabolic features from both ascendants in reaction
content (Fig. 3C and SI Appendix, Fig. S2), subsystem coverage (SI
Appendix, Fig. S3), and metabolic task performance (SI Appendix,
Fig. S4). In summary, the comparison of these context-specific
GEMs revealed distinct metabolism between the neuronal cells
of APP overexpression and Trem2KO models.
Enrichment analysis conducted with various gene-set collections
also showed distinct metabolic differences between APP over-
expression and Trem2KO models (SI Appendix, Fig. S5). Among
the APP overexpression models, substantial expression profile
changes were observed along with Aβ deposition, including the up-
regulation of pathways in apoptosis, signaling, cholesterol homeo-
stasis, innate immune system, allograft rejection, inflammatory and
interferon response, and a number of energy metabolism and
neurogenerative diseases (SI Appendix, Fig. S5). To pinpoint the
altered metabolic processes associated with Aβ deposition we
performed comparative analysis of subsystems (SI Appendix, Fig.
S6) and reporter metabolite gene sets (Fig. 3D). The oxidative
phosphorylation, amino acid metabolism, fatty acid oxidation,
and cholesterol metabolism were identified as prominently up-
regulated during the progression of AD (SI Appendix, Fig. S6).
This is consistent with the down-regulation of mitochondrial me-
tabolite gene sets associated with energy metabolism in the AD
models before the onset of Aβ deposition (Fig. 3D). The alteration
patterns of these metabolic pathways were also consistent with that
found in the previous enrichment analysis (SI Appendix, Fig. S5), as
well as the tissue-specific GEM comparison (Fig. 3C and SI Ap-
pendix, Fig. S3). With gene–reaction–metabolite connectivity of
GEMs, gene sets associated with each metabolite can be obtained
and subjected to enrichment analysis that may reveal insights into
Wang et al. PNAS | 3 of 9

















































Fig. 2. Systematic comparison and evaluation of generic model animal GEMs. (A) Significantly altered subsystems with deviated reaction content between
the newly generated GEMs and Human1. The color indicates the percent difference in the number of reactions within each subsystem for a GEM compared to
the mean number of reactions in that subsystem across all GEMs. Radar plots showing the comparison in the numbers of reactions, metabolites, genes, and
enzyme complexes that have a GPR with “and” relation, as well as benchmarking MEMOTE scores between the GEMs for (B) mouse, (C) rat, (D) zebrafish, (E)
fruit fly, and (F) worm. (G) Evaluation of gene essentiality prediction performance among GEMs of mouse, fruit fly, and worm using the MCC, which scores the
relative amount of true and false positive and negative predictions of gene essentiality.
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network level alterations of given expression data. Notably, the gene
sets of reporter metabolites (GM2A, H+, Pi, H2O, ADP, and ATP)
associated with lysosome (Dataset S3) were uniformly enriched in
the APP overexpression models after Aβ deposition but absent
from the hybrid Trem2 KO (KOMP) × APPPS1 model (Fig. 3D).
Aβ Accumulation Activates Gene Expression in Lysosomal Pathways of
GM2 Gangliosides and Peptide Degradation.By integrative analysis of
reporter metabolite gene sets with Mouse1 we discovered an up-
regulated GM2A-centric lysosomal subnetwork shared between




Fig. 3. RNA-seq data integration and gene set analysis using Mouse1. (A) Various AD models of transgenic mice have been developed to recapitulate the
pathology of Aβ deposition and subsequent phenotypes of subsequent neuroinflammation and cognitive impairment. (B) RNA-seq datasets from transgenic
and wild-type mice with paired time points were selected for studying the metabolic changes associated with AD progression. The colored symbols are used to
depict the different datasets and their sampling time points in relation to the onset and progression of Aβ deposition, which is illustrated by a shaded
background (Dataset S3). (C) Structural comparison of tissue/cell type-specific GEMs using t-distributed stochastic neighbor embedding (tSNE) analysis. (D)
Reporter metabolite gene set analysis using Mouse1. The log-transformed Penrich value quantifies the significance of substantially up- (in positive values) or
down-regulated (in negative values) gene sets between diseased and normal conditions. Subcellular compartment is indicated in brackets, in which l, m, and c
refer to lysosome, mitochondrion, and cytosol, respectively. *The full names of the CoA metabolites are (6Z,9Z,12Z,15Z)-octadecatetraenoyl-CoA,
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl-CoA, and (7Z)-octadecenoyl-CoA and (6Z,9Z)-octadecadienoyl-CoA, respectively.
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subnetwork was not enriched in the data from Trem2KO models,
as well as the conditions prior to Aβ plaque formation in APP
overexpression models (SI Appendix, Fig. S8). It therefore
appeared to be the signature response induced specifically by Aβ
accumulation. By inspecting the expression pattern of the lyso-
somal genes across the collected AD models we confirmed their
consistent up-regulation in APP overexpression models and only
after the onset of Aβ deposition (Fig. 5A). Within the APP models,
a higher magnitude of fold change of lysosomal genes was observed
in APPPS1 compared to APP23 and APPswe/PSEN1dE9. Among
the four time points from the APP23 model data (GSE80465), the
up-regulation of the lysosomal genes peaked at 18 mo, whereas
they appeared to slightly decrease in a later stage at 24 mo. In
contrast, only marginal changes were observed in the APPswe/
PSEN1dE9 (line 85) model (GSE136861), which were sampled
with four time points (2, 4, 5, and 6 mo) when Aβ plaques have not
been formed in the brain of transgenic mice (Dataset S3).
Validation of Activated Lysosomal Degradation Pathways Using
Proteomics Data from AD Models. To validate the activation of
the lysosomal degradation pathways at the protein level we
reanalyzed proteomics datasets obtained from brain tissues of
another five APP overexpression models: hAPP, hAPP/PS1,
5xFAD, ADLPADP, and ADLPAPP/PS1 (Fig. 5B and Dataset S3).
Despite the different methods of mass spectrometric detection
and quantification, a concerted up-regulation of the candidate
lysosomal digestive enzymes, except Nme4, was observed among
the differentially expressed proteins between transgenic versus
wild-type mice at different time points (Fig. 5C). In 5xFAD,
ADLPAPT, and ADLPAPP/PS1 models, AD progression was clearly
accompanied by an increase of these lysosomal proteins in fold
APPPS1 APPswe/PSEN1dE9A B
C
Down-regulation                        Up-regulation
APP23 GSE80465 Forebrain M 18mo




















































Fig. 4. Integrative analysis of reporter metabolite gene sets with Mouse1. The up-regulation of a GM2A-centric subnetwork in lysosome is identified as a
signature response to in APP overexpression models: (A) APPPS1, (B) APPswe/PSEN1dE9, and (C) APP23. This subnetwork, indicated by a dashed box, was
found to be the most significant and consistent metabolic change to Aβ deposition. The nodes depict significantly changed reporter metabolite gene sets
(cutoff: P < 0.002), each of which comprises all genes associated with reactions in which one metabolite is involved. The node color reflects directionality score
that indicates the overall differential direction of the gene set, ranging from down- (blue) to up-regulation (red). The node sizes are proportional to
the −log10p values of corresponding gene sets, and the edge width indicates the number of reactions shared by the metabolites. (D) The diagram depicts the
lysosomal degradation pathways that were detected from the elevated mouse genes through integrative analysis.
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changes compared to the wild-type conditions. This suggests the
potential application of their corresponding human orthologs,
such as CTSS, as biomarkers for early diagnosis.
Investigation of Lysosomal Peptide Concentrations in Cerebrospinal
Fluid Samples of AD Patients. Since our approach ensured a con-
sistent namespace and nomenclature between Human1 and new
animal GEMs, this enables convenient translation of results from
animal model experiments to human validation. Consequently,
we sought to investigate the expression levels of these lysosomal
enzymes in human samples. By analyzing a dataset from a recent
study that quantified 51 targeted peptides in the cerebrospinal
fluid samples from AD patients and healthy controls (38), we
found that peptides from GM2A, CTSB, and CTSD were sig-
nificantly enriched in AD patients compared to those from
healthy individuals (SI Appendix, Fig. S9), supporting the asso-
ciation of altered lysosomal function in AD patients.
Discussion
In this study we presented a robust animal GEM development
pipeline with which the most comprehensive GEMs (Mouse1,
Rat1, Zebrafish1, Fruitfly1, and Worm1) for five major model
animals were generated and maintained (Fig. 1 and SI Appendix,
Fig. S1). With significantly expanded coverage of metabolic
components compared to previously reported GEMs (Fig. 2 and
Dataset S1), these new GEMs collectively serve as a coherent
platform allowing systematic integration of high-throughput
omics data from a wealth of disease models. These GEMs,
capturing both the orthology-based metabolic network and
species-specific pathways (Fig. 1) that can be interactively que-
ried through the accompanying web portal Metabolic Atlas (11),
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Fig. 5. Validation of elevated lysosomal enzymes at the RNA and protein level. (A) Log2 fold changes of lysosomal genes (Gm2a, Hexa, Hexb, Ctsb, Ctsc, Ctsd,
Ctsf, Ctss, Ctsz, and Nme4) that are involved in GM2 ganglioside and peptide degradation. The data from each AD model are displayed in the order of
sampling time, while the onset of Aβ deposition is indicated by a dashed red line. (B) Bar plot showing the number of significantly (P < 0.05) up-regulated
lysosomal enzymes from five APP overexpression mouse models (hAPP, hAPP/PS1, 5xFAD, ADLPAPPPS1, and ADLPAPT) (Dataset S4). (C) Heat maps showing the
fold changes of these significantly up-regulated lysosomal enzymes along AD progression.
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will evolve as a continuously expanding knowledgebase for the
study of animal metabolism.
We demonstrated a specific case of using Mouse1 through a
systems biology approach with omics data integration (Fig. 3).
There exists an abundance of rodent models developed by in-
troducing AD risk genes (35) that include APP and presenilin
1 and 2 (PSEN1 and PSEN2), which have been determined
to cause Aβ deposition in familial forms of AD (39), and
other susceptible genes (e.g., TREM2) that were associated with
sporadic AD (40, 41). Both APP overexpression and Trem2KO
models, as well as the hybrid one Trem2KO × APPPS1 (42),
were investigated to evaluate their metabolic features in terms
of the different genetic backgrounds (Fig. 3 and SI Appendix,
Figs. S2–S4). The illustration of model-specific changes revealed
their distinct metabolism, supporting the claim that each model
can only recapitulate partial AD pathologies (43). This fur-
ther stresses the necessity of an integrative evaluation of dif-
ferent transgenic animals, and our GEM-based in silico analysis
was shown to be very useful in characterizing various animal
models of the same disease in their metabolic capacity and
guiding downstream investigations toward targeted clinical
application.
Aβ plaque formation increases with age in both transgenic
mice and AD patients (6), making APP overexpression models
useful tools in elucidating the temporal development of AD in
human brain (35). Assisted by the comprehensive coverage of
metabolic genes in Mouse1, a subnetwork of lysosomal degra-
dation pathways was identified as a signature response to Aβ
deposition across the APP overexpression models (Fig. 4 and SI
Appendix, Fig. S7). The lysosomal pathways appeared to be ac-
tivated immediately with the onset of Aβ deposition and sus-
tained throughout the progression of AD in transgenic mice
(Fig. 5). The increased transcription and translation of individual
lysosomal components were previously detected in brains of AD
and other neurodegenerative disease patients (44). This is con-
sistent with the observation of reduced Aβ levels in the brain of
transgenic mice after in vivo up-regulation of lysosomal activities
(45). In particular, our findings address lysosomal genes hydro-
lyzing GM2 gangliosides and peptides (Fig. 4D), whose homeo-
stasis in neurons is essential for brain maintenance (46).
Gangliosides are abundant in brain tissue and constitute ∼10 to
12% of the lipid content in neuronal membranes (47). The
content and composition of gangliosides decrease dramatically
during aging (48). The GM2A, HEXA, and HEXB genes encode
enzymes responsible for degradation of GM2 gangliosides, mu-
tations obstructing this pathway induce neurodegenerative dis-
orders, including Tay–Sachs disease, AB variant, and Sandhoff
disease (49). Similarly, cysteine cathepsins CtsB/L have been
demonstrated as essential in lysosomal degradation of Aβ pep-
tides in mouse embryonic fibroblasts (50). In vitro screening also
showed that CtsB and CtsL can proteolyze α-synuclein amyloid
fibrils that are closely associated with neurodegeneration in
parkinsonian disorders, while CtsD requires the assistance of
anionic lipids for the hydrolysis (51). Collectively, a strong cor-
relation between AD and endolysosomal activities has been
established with a growing number of studies. Previously, genetic
deficiency of lysosomal genes was speculated as the cause of
endolysosomal and autophagic dysfunction that subsequently
drives AD progression (52). Using a systematic analysis of AD
models with and without Aβ plaques, however, our results
suggests that up-regulation of lysosomal degradation pathways
occurs downstream of Aβ deposition, such that elevated ex-
pression of lysosomal genes is a result of AD pathogenesis
rather than a cause. Also, lysosomal dysfunction appears to be
involved as a cascading effect of Aβ deposition and worth
continued exploration.
Biomarkers for an early diagnosis are urgently needed for AD
due to the lack of effective treatments (53). There are currently
three well-established biomarkers of lower Aβ42 levels and
higher levels of total and phosphorylated tau for AD diagnosis
(54). By translating the metabolic alterations obtained from
analyzing AD models with Mouse1 (Fig. 5), here we presented a
collection of nine lysosomal enzymes as potential biomarkers, of
which CSTD has been previously verified in cerebrospinal fluid
(55) and plasma samples (56), while the others represent new
candidates. Our statistical analysis showed that the peptides of
CTSB, CTSD, and GM2A in cerebrospinal fluid samples of AD
patients are significantly increased compared to those in healthy
controls (SI Appendix, Fig. S9). In addition, the rapid elevation
of expressed lysosomal genes following Aβ deposition in mouse
models also suggests that these lysosomal enzymes may be up-
regulated in the prodromal phase of AD (Fig. 5). This is in good
agreement with the longitudinal analysis of plasma CSTD levels,
which were sampled from the same patients at preclinical phase
and after diagnosed as AD (with an interval of 1 to 10 y), and
both were significantly elevated in comparison to that in healthy
controls (56). Taken together, the presented lysosomal enzymes
identified with altered expression by the approach of systems
medicines constitute potential body fluid biomarkers that may be
utilized for early-stage AD diagnosis.
In summary, we presented tissue- and time-dependent varia-
tions of AD mice and reported candidate biomarkers through
integrative analysis of omics data with animal GEMs. By asso-
ciating gene expression changes to subsystem and metabolite
levels, this study demonstrated how results from model or-
ganism can be translated to clinical implications in human.
Next, it is expected that the discovered disease-specific patterns
and biomarkers could be inspected with large-scale compara-
tive analysis of human datasets and body fluid samples for
further verification. For quantitative flux predictions, we sug-
gest contextualizing (e.g., tINIT) these GEMs with omics data
and/or using the GECKO enzyme-constraint framework (57).
Along with the rapidly growing omics data, we are confident
that the set of animal GEMs will be a valuable platform
assisting translational studies toward developing clinical treat-
ments for a wide range of human diseases.
Materials and Methods
All the materials and methods are detailed in SI Appendix: generation,
comparison, and evaluation of animal GEMs; development of Metabolic
Atlas 2.0; RNA-seq data retrieval and differential expression analysis; gene
set and network integrative analysis; proteomics data investigation; and
statistical analyses. All GEM simulations were carried out in MATLAB using
RAVEN toolbox (27) with the Gurobi solver (Gurobi Optimization, LLC).
Data Availability. The GEMs for Mouse1, Rat1, Zebrafish1, Fruitfly1, and Worm1
are available on GitHub at https://github.com/SysBioChalmers/Mouse-GEM,
https://github.com/SysBioChalmers/Rat-GEM, https://github.com/SysBioChalmers/
Zebrafish-GEM, https://github.com/SysBioChalmers/Fruitfly-GEM, and https://
github.com/SysBioChalmers/Worm-GEM, respectively. The code for GEM devel-
opment is available at https://github.com/SysBioChalmers/Human-GEM. The tis-
sue- and cell-type-specific GEMs for transgenic mice and code for integrative
analysis are available at https://github.com/SysBioChalmers/Mouse-GEM. All
other data are available in supporting information.
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